EQRx Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
300
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.07B
- Investors
-
3
EQRx General Information
Description
EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.
Contact Information
Website
www.eqrx.comCorporate Office
- 50 Hampshire Street
- Cambridge, MA 02139
- United States
Corporate Office
- 50 Hampshire Street
- Cambridge, MA 02139
- United States
EQRx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 09-Nov-2023 | $1.07B | Completed | Generating Revenue | ||
| 4. PIPE | 17-Dec-2021 | Completed | Generating Revenue | |||
| 3. Reverse Merger | 17-Dec-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 11-Jan-2021 | $570M | $770M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 12-Jan-2020 | $200M | $200M | Completed | Startup |
EQRx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
EQRx Comparisons
Industry
Financing
Details
EQRx Competitors (1)
One of EQRx’s competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Altimmune | Formerly VC-backed | Gaithersburg, MD |
EQRx Signals
EQRx Former Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Andreessen Horowitz | Venture Capital | Minority | ||
| Arboretum Ventures | Venture Capital | Minority | ||
| Avidity Partners | Asset Manager | Minority |
EQRx Investments & Acquisitions (4)
EQRx’s most recent deal was a Merger/Acquisition with CM Life Sciences III. The deal was made on 17-Dec-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CM Life Sciences III | 17-Dec-2021 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Siduma Therapeutics | 16-Nov-2021 | Early Stage VC | Drug Discovery | ||
| Hansoh Pharmaceutical (Aumolertinib License) | 22-Jul-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Crimson BioPharm | 04-Oct-2019 | Seed Round | Pharmaceuticals |
EQRx ESG
Risk Overview
Risk Rating
Updated June, 30, 2023
27.56 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
EQRx FAQs
-
When was EQRx founded?
EQRx was founded in 2019.
-
Where is EQRx headquartered?
EQRx is headquartered in Cambridge, MA.
-
What is the size of EQRx?
EQRx has 300 total employees.
-
What industry is EQRx in?
EQRx’s primary industry is Drug Discovery.
-
Is EQRx a private or public company?
EQRx is a Private company.
-
What is the current valuation of EQRx?
The current valuation of EQRx is .
-
What is EQRx’s current revenue?
The current revenue for EQRx is .
-
How much funding has EQRx raised over time?
EQRx has raised $1.97B.
-
Who are EQRx’s investors?
ARCH Venture Partners, Alexandria Venture Investments, Andreessen Horowitz, Arboretum Ventures, and Avidity Partners are 5 of 24 investors who have invested in EQRx.
-
Who are EQRx’s competitors?
Altimmune is a competitor of EQRx.
-
When was EQRx acquired?
EQRx was acquired on 09-Nov-2023.
-
Who acquired EQRx?
EQRx was acquired by Revolution Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process